about
Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophiliaTriheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplementClinical genomics: when whole genome sequencing is like a whole-body CT scan.Performance of exome sequencing for pharmacogenomics.Multi-Institutional FASTQ File Exchange as a Means of Proficiency Testing for Next-Generation Sequencing Bioinformatics and Variant Interpretation.JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE.Miniaturized detection technology in molecular diagnostics.Patient Privacy and Clinical Laboratory Data.Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.Regulation of mechanosensitive biliary epithelial transport by the epithelial Na(+) channel.Case report and review of lupus erythematosus cells in cytology fluids.Review article: the global emergence of Helicobacter pylori antibiotic resistance.Morphologic characterization of syndromic gastric polyps.Celiac disease: clinical, endoscopic, and histopathologic review.Review of autoimmune metaplastic atrophic gastritis.Prospects for the commercialization of chemiluminescence-based point-of-care and on-site testing devices.β-Globin gene sequencing of hemoglobin Austin revises the historically reported electrophoretic migration pattern.The future of laboratory medicine - a 2014 perspective.Human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinomas: role of the gastroenterologist.Novel Helicobacter pylori sequencing test identifies high rate of clarithromycin resistance.Gastric pyloric gland adenoma.Precision Medicine in Gastrointestinal Pathology.Nanostructured luminescently labeled nucleic acids.Clinical significance of isolated cytomegalovirus-infected gastrointestinal cells.Clinical exome performance for reporting secondary genetic findingsHelicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.Characterization of the HBB: c.*233G > C Variant: No Evidence of a β-Thalassemic Phenotype.Investigation of Linezolid Resistance in Staphylococci and Enterococci.Applying the Principles of Lean Production to Gastrointestinal Biopsy Handling: From the Factory Floor to the Anatomic Pathology Laboratory.Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2.Development and validation of a quantitative real time PCR assay for BK virus.Chemiluminescence-based detection of gastrointestinal malignancies.Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood.Nucleotide requirements for CDX2 binding to the cis promoter element mediating intestine-specific expression of guanylyl cyclase C.Next-generation sequencing in the clinic.Additive-aggravated assays: an authoritative answer.Intersection of DNA privacy and whole-genome sequencing.Abdominal Angiostrongyliasis: A Presentation of Eosinophilic Granulomatous Colitis.Obtaining Adequate Lamina Propria for Subepithelial Fibrosis Evaluation in Pediatric Eosinophilic Esophagitis.Red-shifted emission from 1,2-dioxetane-based chemiluminescent reactions.
P50
Q33838272-F874834D-B935-421B-82A1-02A9E68AFD3EQ35223033-BC24D1DF-C115-4DE6-B3E2-559A1EF9A806Q35413254-9E449330-5EA5-49BA-A1A0-CBED7A6A3D56Q35919636-B5473BEC-B7AC-481D-AED6-4A580238BECBQ36011406-AB4A5085-30F6-4D0D-A42E-40F400574C2EQ36054472-6E32020A-1541-4755-95E5-13EDEB445B20Q36192711-EC11519D-927E-4E6D-A501-BF1310AA46EFQ36394465-943419C5-EAFE-41DD-B00E-635A0C3DBA84Q36526265-DC3B3147-2423-4759-B307-0806DB91C8BBQ36659220-CA9736E9-7444-4403-8063-36D0A81C4576Q37002929-3B7C74B4-06B6-4202-B87B-C7CB8F989E67Q37340339-BF0E0963-96FB-4121-A006-EE622484F9E2Q37798129-F632B36B-0E1D-42E8-90C2-796B9BC34202Q38035125-88B5E5F2-0434-47F5-BBD2-24EF8F51D5E2Q38064018-58EFBE94-1D1D-4CFF-9701-20B7172736B0Q38198501-38DFF954-FFC5-461E-B768-4B0B6E3DF987Q38216083-235211C3-419C-460A-B76F-6495BD861191Q38249014-0395389D-DCB9-498C-BF9F-7ACEEA6577A2Q38389713-5B6A0BF8-4685-44B5-8A64-E4968B3E5013Q38390116-6FD7E6D8-9820-4D79-8D09-5A747655269BQ38510555-7906E435-3357-455A-B24B-86996EC534C0Q38820841-4BE6AA4A-2312-431B-B7B0-65C0F37E85F3Q38896961-49554CC9-1A64-4BBC-8BB0-6B4247A2E9D7Q39181570-EDF81EEB-85FA-42A3-A774-ABBE1C94D37EQ39824867-CA25AA69-24F3-43FA-AAA7-E3BBBC0EA664Q39961975-D21269FD-9B0B-4C58-B302-7DDF3EC40F47Q40366583-05F88C06-9763-4832-B7AF-5907CE7DE715Q40616680-F74C02F2-1367-468E-99C4-204A37C31AFFQ40710228-DCD8D507-64C9-4204-A626-E730DE83D49BQ40869146-839AFDBD-9F47-4533-B5EC-0E381DAC8C3CQ42249981-C8EECF38-9E69-43E5-88DF-CBD05F82EF3FQ43261896-70EC1C35-513E-4E4D-83AD-C7BCED92051AQ43752305-49700319-68AC-4444-9BCF-0AFE2DC683F0Q43782738-93866D63-CA38-4784-8550-9FF779FC5576Q45744426-B83821A2-B45A-4040-9192-001879689390Q46724625-DDA0DFBA-0254-4FB5-83BE-1AE85169F8E9Q48050551-75E4C62B-6CD9-48D3-A16D-8798D1874997Q48347587-5A962305-FAE2-43DD-A29B-C17F0731C206Q50138161-4D519DB0-1648-4E83-9862-CE488B998B08Q50473107-C2E619CC-FD2B-42C9-A08C-9E3B479E1825
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Jason Y. Park
@en
Park JY
@ast
Park JY
@es
Park JY
@nl
type
label
Jason Y. Park
@en
Park JY
@ast
Park JY
@es
Park JY
@nl
altLabel
Park JY
@en
prefLabel
Jason Y. Park
@en
Park JY
@ast
Park JY
@es
Park JY
@nl
P106
P1153
37023779300
P31
P496
0000-0001-6797-4000